Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Bitcoin Trust (IBIT) vs Novavax Inc (NVAX) Price & Performance

iShares Bitcoin TrustTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

iShares Bitcoin Trust vs Novavax Inc — how do they compare? iShares Bitcoin Trust trades at $46.61 (market cap $67.31B), while Novavax Inc trades at $12.83 (market cap $1.82B). The key difference: iShares Bitcoin Trust is far larger — about 37× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 40 Days and Novavax Inc for 59 Days on average.

IBITNVAX
Market Cap
$67.31B$1.82B
Volume
56,154,5446,198,505
Sector
Crypto-linkedHealth
52-Week High
$68.74$12.56
52-Week Low
$33.29$6.22
Typical Hold Time
40 Days59 Days
Enterprise Value
—$1.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Bitcoin Trust

IBIT trades at $46.79, down 0.89% with bearish technical signals from oscillators and mixed moving averages. Recent news highlights significant institutional inflows, including a $196 million single-day inflow on October 1, 2026. The stock faces resistance at $47-$48 with support at $44-$46, while RSI levels suggest potential oversold conditions. Financial ratios remain undisclosed in current data.

Outlook hinges on sustained institutional interest amid volatile ETF flows, with Q3 inflows reversing prior outflows. Risks include fee structures impacting returns and market sentiment shifts. Upside potential exists if Bitcoin ETF momentum continues, but investors face exposure to crypto market volatility without direct cash flow benefits.

Novavax Inc

Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.

Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IBIT
75% Buy25% Sell
Avg holding period · 40 Days
NVAX
55% Buy45% Sell
Avg holding period · 59 Days

Top news

Latest headlines on both assets

About iShares Bitcoin Trust

IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.

Read more on IBIT →

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX →